SCOPUS 정보 검색 플랫폼

Volumn 5, Issue 1, 2004, Pages 28-30

CHF 3381

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CHF 3381; DIZOCILPINE; LAMOTRIGINE; MONOAMINE OXIDASE INHIBITOR; N (2 INDAN 2 YL)GLYCINAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANTICONVULSANT ACTIVITY; ARTICLE; ASTHENIA; CLINICAL TRIAL; COGNITIVE DEFECT; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DESIGN; DRUG HALF LIFE; DRUG METABOLISM; DRUG RECEPTOR BINDING; EPILEPSY; HUMAN; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PATENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEIZURE;

ANIMALS; DRUGS, INVESTIGATIONAL; GLYCINE; HUMANS; INDANS; MONOAMINE OXIDASE INHIBITORS; PAIN;

EID: 1042269527 PISSN: 11745886 EISSN: None Source Type: Journal
DOI: 10.2165/00126839-200405010-00005 Document Type: Article

Times cited : (3)

References (7)

1
- 24844476013
- Chiesi's new treatment for neuropathic pain proceeds to proof-of-concept study
- Chiesi Farmaceutici. Media Release: 3 Jun Available from URL
- Chiesi Farmaceutici. Chiesi's new treatment for neuropathic pain proceeds to proof-of-concept study. Media Release: 3 Jun 2003. Available from URL: http://www.chiesigroup.com/
- (2003)

2
- 1042299728
- CHF 3381: Non-confidential product profile
- Chiesi Farmaceutici. Company Communication: [8 pages], 13 May
- Chiesi Farmaceutici. CHF 3381: non-confidential product profile. Company Communication: [8 pages], 13 May 2003
- (2003)

3
- 1042288030
- Interspecies comparison of in vitro and in vivo metabolism of CHF 3381
- (Additional abstracts), May
- Rondelli I, Puccini P, Marchetti S. Interspecies comparison of in vitro and in vivo metabolism of CHF 3381. European Journal of Pharmaceutical Sciences 8: (Additional abstracts), May 1999
- (1999) European Journal of Pharmaceutical Sciences , vol.8
- Rondelli, I.¹ Puccini, P.² Marchetti, S.³

4
- 0034982869
- Preclinical evaluation of CHF3381 as a novel antiepileptic agent
- Jun
- Villetti G, Bregola G, Bassani F, et al. Preclinical evaluation of CHF3381 as a novel antiepileptic agent. Neuropharmacology 40: 866, Jun 2001
- (2001) Neuropharmacology , vol.40 , pp. 866
- Villetti, G.¹ Bregola, G.² Bassani, F.³

5
- 12444329963
- Mechanisms of action of CHF3381 in the forebrain
- Aug
- Barbieri M, Bregola G, Buzzi A, et al. Mechanisms of action of CHF3381 in the forebrain. British Journal of Pharmacology 139: 1333-1341, No. 7, Aug 2003
- (2003) British Journal of Pharmacology , vol.139 , Issue.7 , pp. 1333-1341
- Barbieri, M.¹ Bregola, G.² Buzzi, A.³

6
- 0037113355
- Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist
- 15 Nov
- Zucchini S, Buzzi A, Bergamaschi M, et al. Neuroprotective activity of CHF3381, a putative N-methyl-D-aspartate receptor antagonist. Neuroreport 13: 2071-2074, 15 Nov 2002
- (2002) Neuroreport , vol.13 , pp. 2071-2074
- Zucchini, S.¹ Buzzi, A.² Bergamaschi, M.³

7
- 0037961047
- Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel n-methyl-d-aspartate antagonist, after single oral doses in healthy subjects
- Aug
- Tarral A, Dostert P, Guillevic Y, et al. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel n-methyl-d-aspartate antagonist, after single oral doses in healthy subjects. Journal of Clinical Pharmacology 43: 901-911, No. 8, Aug 2003
- (2003) Journal of Clinical Pharmacology , vol.43 , Issue.8 , pp. 901-911
- Tarral, A.¹ Dostert, P.² Guillevic, Y.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.